CLDX News & Events

Relief rally discounting de-escalation in the Middle East continued on Wednesday, with investors sending the Nasdaq Composite up 1.2% and S&P 500 up 0.7 in the first trading day of the new quarter.  Materials was once again among the best performing sectors on the benchmark, with State Street Materials Select Sector SPDR ETFnow up over 3% from Friday's lows following three sessions of gains.  Energy, meanwhile, entered the new quarter as the worst performing sector on the day as WTI Crude Oil prices continued to fall, sliding back below $100 per barrel on diminishing geopolitical premium.Ahead of this evening's address by President Trump updating the nation on the cabinet's plans for Iran, equity futures are little changed, with S&P e-minis at 6,617 and Nasdaq 100 contract around 24,190.  May WTI Crude Oil has also resumed quotation to the downside and below $99 while precious metals are advancing for the 5th consecutive session - Gold is above $4,820 and Silver is just shy of the $76 per ounce mark.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Franklin Coveyup 11.4%Penguin Solutionsup 10.7%ALSO HIGHER -Globalstarup 15.3% after FT reports Amazon.com is in talks to acquire companyWingstopup 1.8% after valuation-driven Piper Sandler upgrade to OverweightDOWN AFTER EARNINGS -Bassett Furniture Industriesdown 3.8%ALSO LOWER -Celldex Therapeuticsdown 5.3% after equity offeringAlto Neurosciencedown 3.0% after announcing ALTO-101 did not achieve statistical significance

Celldex Therapeutics announced that it has commenced an underwritten public offering for the sale of shares of its common stock. Celldex currently intends to use the net proceeds of this offering, together with its existing cash, cash equivalents, and marketable securities, (i) to fund ongoing commercial readiness activities and the commercial launch of barzolvolimab, if approved, for the treatment of CSU in the United States, (ii) to continue the clinical and preclinical development of its product candidates, including current and future development of barzolvolimab, (iii) to grow its bispecific antibody platform and clinical candidates, (iv) to fund ongoing efforts to develop additional clinical pipeline product candidates and (v) for general corporate purposes. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the proposed offering.

Celldex presented additional data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria and cold urticaria and symptomatic dermographism demonstrating profound improvements in patient quality of life across all measured domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD-the mast cell. The data were presented at the 2026 Americal Academy of Dermatology Annual Meeting being held March 27 - 31, 2026 in Denver, CO. In the post hoc analysis presented at AAD, the impact of disease on QoL for the subset of patients who received 52 weeks of barzolvolimab therapy and completed treatment with at least well controlled disease at Week 52 and had DLQI data through Week 76 was explored. The vast majority of patients included in this analysis had substantial disease burden at baseline and patients had CSU for a long time. Patients reported that their CSU had a very large negative impact on their QoL. At Week 52, 94% of patients with well controlled disease at Week 52 also had a DLQI of 0/1, indicating their disease had no impact on their QoL . Barzolvolimab treatment led to prolonged, off-treatment enhanced QoL seven months after the last dose of barzolvolimab. At baseline, patients reported their CSU significantly impacted their QoL across all 6 DLQI domains. Profound improvements were observed across all 6 domains at both Weeks 52 and 76. 76% of patients with well controlled disease at Week 52 also reported that the disease had small to no impact on their QoL at Week 76. The majority of patients with well controlled disease at Week 52 achieved DLQI domain scores of 0/1 at Week 76. This sustained off-treatment improvement in QoL was observed despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification and supports barzolvolimab's significant potential to become a transformative treatment option for patients suffering from CSU.